Navigation Links
ImaRx Therapeutics Signs Letter of Intent With Microbix Biosystems for the Sale of Urokinase
Date:5/7/2008

Microbix to Acquire Commercialized Thrombolytic and Related Assets for $17

Million

TUCSON, Ariz., May 7 /PRNewswire-FirstCall/ -- ImaRx Therapeutics, Inc. (Nasdaq: IMRX) today announced that it has signed a letter of intent in which Microbix Biosystems will acquire urokinase inventory and related assets from ImaRx for $17 million in cash. Urokinase is an FDA-approved thrombolytic, or clot-dissolving agent, indicated for the treatment of acute massive pulmonary embolism. ImaRx acquired an approximate four year inventory of the product from Abbott Laboratories and has been selling the product from inventory since 2006.

Bradford A. Zakes, President and CEO of ImaRx, stated, "The proceeds to be generated through this transaction provide ImaRx with a solid source of non- dilutive financing. We are very pleased with the terms under which we have reached agreement with Microbix on the sale of our urokinase asset. Through this transaction, ImaRx will have gained access to operating capital under favorable economic terms that will enable the company to continue the advancement of our core SonoLysis technology."

Under terms of the agreement, Microbix will acquire the urokinase product and related assets for an upfront payment of $12 million plus an additional $5 million upon achievement of an inventory stability milestone. Upon closing, Microbix will assume full responsibility for urokinase, including sales, marketing and regulatory compliance requirements. To facilitate the inventory stability milestone, Microbix will engage ImaRx in a support services agreement.

ImaRx had previously announced in January 2008 that it had signed a letter of intent to partner with Microbix in the transfer
'/>"/>

SOURCE ImaRx Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. ImaRx Therapeutics Satisfies Abbott Note Obligation Associated With the Acquisition of Urokinase
2. ImaRx Therapeutics Receives Notification from NASDAQ Regarding Non-Compliance with NASDAQs Minimum Bid Price Requirement
3. ImaRx Therapeutics Reports Business Update and Financial Results for Fourth Quarter and Full Year 2007
4. ImaRx Reschedules Release of Corporate Updates and Fourth Quarter and Full Year 2007 Financial Results
5. ImaRx to Report Corporate Updates and 4Q07 Financial Results
6. ImaRx Therapeutics Receives Urokinase Lot Release Approval With Extended Expiration Dating
7. Lorus Therapeutics Strengthens Its Senior Management Team Through Internal Promotions
8. Cell Therapeutics, Inc. (CTI) to Report 2008 First Quarter and Financial Results on May 8
9. European Regulatory Agency Supports OPAXIO(TM) Brand Name for Cell Therapeutics Lung Cancer Drug
10. HER1 and HER3 VeraTag(TM) Assays are Now Available for Use in Development and Clinical Evaluation of Cancer Therapeutics
11. United Therapeutics Announces the Results of Its 2008 Annual Meeting of Shareholders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... July 24, 2014 -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) (the ... randomized, active control Phase 3 study of Zerenex (ferric ... for the treatment of hyperphosphatemia in patients with end-stage ... binding and iRon delivery with FErric CiTrate in EsrD) ... the American Society of Nephrology ( JASN ). ...
(Date:7/24/2014)... , July 24, 2014  Asterias Biotherapeutics, Inc. ... emerging field of regenerative medicine, announced today that ... presentation to investors on Tuesday, July 29, 2014, ... presentation will include an overview of Asterias, business ... webcast, visit http://www.ustream.tv/channel/asterias-biotherapeutics at least 15 ...
(Date:7/24/2014)... Yet, scientists are making progress in devising suitable ... approach relies on quantum dotsa kind of artificial ... A new study demonstrates that changing the coupling ... electrical impulses can help better control them. This ... as quantum information units, which would produce faster ...
(Date:7/24/2014)... 2014 Research and Markets has ... Proteomics Analytical Instruments Market 2014-2018" report to their ... Genomics is the study of the gene and ... structure and functions of proteomes or sets of proteins ... Genomics involves the mapping of genes and DNA sequencing ...
Breaking Biology Technology:Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 4Asterias Biotherapeutics Announces Live Investor Webcast 2Asterias Biotherapeutics Announces Live Investor Webcast 3Asterias Biotherapeutics Announces Live Investor Webcast 4Global Genomics and Proteomics Analytical Instruments Market 2014-2018: Key Vendors are Agilent, Bio-Rad , F. Hoffmann, La Roche, Illumina, PerkinElmer and Thermo Fisher Scientific 2
... Acquisition Extends Elsevier,s Ability to Gather Global Healthcare News and, ... Increase ... Business Value for Customers, PHILADELPHIA, March 10 ... information, announced,today that it has acquired Windhover Information Inc., a ...
... March 10 Caliper Life,Sciences, Inc. (Nasdaq: ... the,Cowen and Company 28th Annual Health Care Conference ... at 2:30 p.m. EDT. Kevin Hrusovsky, President,and CEO ... the company,s business.,The live webcast can be accessed ...
... used by Avexa to select patients and optimize ... background therapy in phase III program, SOUTH SAN FRANCISCO, ... today that the Company,has signed an agreement with AVEXA Limited (ASX: ... technology in support of,Avexa,s drug discovery and development programs., Avexa ...
Cached Biology Technology:Elsevier Acquires Windhover Information Inc., a Healthcare Business Intelligence Company 2Elsevier Acquires Windhover Information Inc., a Healthcare Business Intelligence Company 3Monogram Biosciences and Avexa Announce Exclusive Collaboration to Support New HIV Drug Discovery and Development Efforts 2Monogram Biosciences and Avexa Announce Exclusive Collaboration to Support New HIV Drug Discovery and Development Efforts 3Monogram Biosciences and Avexa Announce Exclusive Collaboration to Support New HIV Drug Discovery and Development Efforts 4Monogram Biosciences and Avexa Announce Exclusive Collaboration to Support New HIV Drug Discovery and Development Efforts 5
(Date:7/27/2014)... Dinosaurs might have survived the asteroid strike that wiped ... or later in history, scientists say. , A fresh ... has helped palaeontologists to build a new narrative of ... , They found that in the few million years ... Earth was experiencing environmental upheaval. This included extensive volcanic ...
(Date:7/27/2014)... the potential for global climate change to cut food ... ignored the interactions between increasing temperature and air pollution ... crops. , A new study involving researchers at MIT ... that policymakers need to take both warming and air ... study looked in detail at global production of four ...
(Date:7/25/2014)... In the first broad-scale estimate of air pollution removal ... calculated that trees are saving more than 850 human ... respiratory symptoms. , While trees, pollution removal equated to ... percent, the impacts of that improvement are substantial. Researchers ... pollution at nearly $7 billion every year in a ...
Breaking Biology News(10 mins):Dinosaurs fell victim to perfect storm of events, study shows 2Study: Climate change and air pollution will combine to curb food supplies 2Study: Climate change and air pollution will combine to curb food supplies 3First national study finds trees saving lives, reducing respiratory problems 2
... (VIB) connected to the University of Antwerp are the first ... cells is a major risk factor for Alzheimer's disease. Amyloid ... of the senile plaques in the brains of patients. The ... protein that is produced, the younger the dementia patient is. ...
... glow emitted by a variety of sea coral helped ... to create a tiny fluorescent tag that responds to ... individual proteins as they dart around inside living cells. ... it is derived from the sea coral Dendronephthya--first shows ...
... to skim through text, instantly recognizing words by their ... after humans evolved. Thus, neuroscientists have hotly debated ... Word Form Area (VWFA) is truly a specific and ... have shown that the area specifically activates when people ...
Cached Biology News:The urban evolution lab 2Sea coral's trick helps scientists tag proteins 2Sea coral's trick helps scientists tag proteins 3'Word-vision' brain area confirmed 2